Publication Name	World Journal of Methodology
Manuscript ID	100074
Country	Qatar

Received	2024-08-22 08:29
Peer-Review Started	2024-08-06 11:19
To Make the First Decision
Return for Revision	2024-09-19 02:04
Revised	2024-09-26 20:48
Second Decision	2024-09-29 02:44
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-09-30 07:37
Articles in Press	2024-09-30 07:37
Publication Fee Transferred
Edit the Manuscript by Language Editor	2024-10-05 21:56
Typeset the Manuscript	2024-10-16 03:37
Publish the Manuscript Online	2024-11-27 10:57

ISSN	2222-0682 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cell & Tissue Engineering
Manuscript Type	Letter to the Editor
Article Title	Evaluating Wharton’s jelly-derived stem cell therapy in autism: Insights from a case study
Manuscript Source	Invited Manuscript
All Author List	Muzamil Akhtar and Abdulqadir J Nashwan
ORCID	Author(s) ORCID Number Abdulqadir J Nashwan http://orcid.org/0000-0003-4845-4119
Funding Agency and Grant Number
Corresponding Author	Abdulqadir J Nashwan, MSc, PhD, Research Scientist, Department of Nursing and Midwifery Research, Hamad Medical Corporation, Rayyan Road, Doha 3050, Qatar. anashwan@hamad.qa
Key Words	Autism spectrum disorder; Stem cell therapy; Neuroinflammation; Neurodevelopmental disorders; Wharton jelly derived mesenchymal stem cell
Core Tip	This letter highlights the groundbreaking study by Kabatas et al, which demonstrates the efficacy and safety of Wharton’s jelly-derived mesenchymal stem cell (WJ-MSC) therapy in improving developmental outcomes for a child with autism spectrum disorder. Despite limitations such as the single-case design and lack of a control group, the study suggests WJ-MSC therapy as a promising treatment option, emphasizing the need for larger, controlled trials to validate these findings and develop standardized treatment protocols.
Publish Date	2024-11-27 10:57
Citation	<p>Akhtar M, Nashwan AJ. Evaluating Wharton’s jelly-derived stem cell therapy in autism: Insights from a case study. <i>World J Methodol</i> 2025; 15(2): 100074</p>
URL	https://www.wjgnet.com/2222-0682/full/v15/i2/100074.htm
DOI	https://dx.doi.org/10.5662/wjm.v15.i2.100074

Full Article (PDF)	WJM-15-100074-with-cover.pdf
Manuscript File	100074_Auto_Edited_034309.docx
Answering Reviewers	100074-answering-reviewers.pdf
Audio Core Tip	100074-audio.mpeg
Conflict-of-Interest Disclosure Form	100074-conflict-of-interest-statement.pdf
Copyright License Agreement	100074-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	100074-non-native-speakers.pdf
Peer-review Report	100074-peer-reviews.pdf
Scientific Misconduct Check	100074-scientific-misconduct-check.png
Scientific Editor Work List	100074-scientific-editor-work-list.pdf
CrossCheck Report	100074-crosscheck-report.png
CrossCheck Report	100074-crosscheck-report.pdf